ORKA | Ticker Profile - Titan Protect

ORKA

Oruka Therapeutics, Inc.

Healthcare · Biotechnology · NGM

$60.14

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.5B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-23.55

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-27.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$141.50

+135% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 12 analysts covering this stock

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

https://orukatx.com

Country: United States Employees: 68 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.994

Good returns relative to risk taken

Kelly Fraction

0.0718

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.801

Acceptable balance between returns and drawdown risk

Annual Return

62.3%

Historical annualised return based on price data

Max Drawdown

-77.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$91.00

34% below the year high

52W Low

$10.64

465% above the year low

Avg Volume

1,470,440

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

15.8%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.93

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.37

Conservative use of debt — low financial risk

Current Ratio

23.76

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

23.38

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-56,126,376

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-94,190,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$200.00

Target Median

$141.50

Target Low

$100.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go